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ILCs can be replenished and complemented,
albeit only in part, through contributions of hema-
togenously derived precursors or mature cells in
situations of extended inflammation and tissue
repair. Consistent with our findings, it has been
reported that ILC subsets are elevated in the pe-
ripheral blood of patients suffering from psoria-
sis (30, 31). Furthermore, peripheral blood ILC2s
have been shown to dynamically modulate the
expression ofmolecules that regulate tissue hom-
ing in mice and humans (20, 32). In addition, we
have detected donor-derived lymphoid and ILC
progenitors in parabiotic BM (fig. S8), raising
the possibility that ILC progenitors can physi-
ologically seed tissues not only during embryonic
development (3) but also in adultmice. It remains
to be determined whether this observation re-
flects the physiologicmigration of ILC progenitors
or the engraftment of donor-derived hematopoietic
stem cells (33, 34) giving rise to ILCs. Indepen-
dent of these considerations, our data support a
model in which ILCs are locally maintained and
expanded as tissue-resident cells during homeo-
stasis and acute infection. This “sedentary” lifestyle
of ILCs in broadly differing microenvironments is
consistent with the proposed roles of ILCs as
sentinels and local keepers of tissue function.
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Patrolling monocytes control tumor
metastasis to the lung
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The immune system plays an important role in regulating tumor growth and metastasis.
Classical monocytes promote tumorigenesis and cancer metastasis, but how nonclassical
“patrolling” monocytes (PMo) interact with tumors is unknown. Here we show that PMo
are enriched in the microvasculature of the lung and reduce tumor metastasis to lung in
multiple mouse metastatic tumor models. Nr4a1-deficient mice, which specifically lack
PMo, showed increased lung metastasis in vivo. Transfer of Nr4a1-proficient PMo into
Nr4a1-deficient mice prevented tumor invasion in the lung. PMo established early
interactions with metastasizing tumor cells, scavenged tumor material from the lung
vasculature, and promoted natural killer cell recruitment and activation. Thus, PMo
contribute to cancer immunosurveillance and may be targets for cancer immunotherapy.
M
onocytes and monocyte-derived mac-
rophages play key roles in tumor pro-
gression (1–4). Classical “inflammatory”
monocytes (CCR2highLy6C+ in mice;
CCR2highCD14+CD16– in humans) are
recruited to tumor sites where they contribute
to macrophage content and promote growth
and metastasis (5, 6). In contrast, very little is
known about the role of nonclassical “patrol-
ling” monocytes (PMo) (CX3CR1highLy6C– in
mice; CX3CR1highCD14dimCD16+ in humans) in
the early growth and metastasis of tumors. PMo
are involved in the resolution of inflammation;
they actively survey the endothelium of the vas-
culature, where they scavenge microparticles and
remove cellular debris (7–9). The orphan nuclear
receptor Nr4a1 (also known as Nur77/TR3/NGIFB)
is highly expressed in PMo compared with other
immune cells and functions as a master regulator
for the development of PMo in mice (10).
To investigate the actions of PMo during early
tumormetastasis, we usedmice expressing green
fluorescent protein (GFP) under the control of
the Nr4a1 promoter (Nr4a1-GFP mice). In these
mice, PMo (but not Ly6C+ classical monocytes)
express high levels of GFP (GFPhigh) (10, 11). We
focused our studies on the lung, which is a com-
mon site of tumor metastasis and an important
locus of PMo activity (12–14). We used flow cy-
tometry to confirm that Nr4a1-GFPhigh cells in
the lung were PMo (fig. S1, A to C). Tracking of
Nr4a1-GFPhigh cells by confocal imaging in the
lungs allowed us to identify a large number of
Nr4a1-GFPhigh PMo patrolling the microvascula-
ture (movie S1 and Fig. 1A). Consistent with an
important role for PMo in the lung vasculature,
we found a three- to fourfold enrichment of
Nr4a1-GFPhigh PMo in the lung compared with
other tissues (fig. S1D).
To examine the interactions of PMo with tu-
mors in vivo, we imaged Nr4a1-GFPhigh PMo in
the lung after intravenous (IV) injection of Lewis
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lung carcinoma cells expressing red fluorescent
protein (LLC-RFP). The number of Nr4a1-GFPhigh
monocytes in the lung increased significantly
24 hours after injection, which implies that PMo
are actively recruited to the lung tumor environ-
ment (Fig. 1A). Within 4 hours after tumor in-
jection,most Nr4a1-GFPhighmonocytes exhibited
decreased patrolling speed in the vasculature,
and by 24 hours they had arrested near lung
tumor sites (Fig. 1B). The majority of Nr4a1-
GFPhigh monocytes isolated from the lung after
LLC tumor transfer maintained their PMo phe-
notype, which we further confirmed in vitro (Fig.
1C and fig. S1).
Nr4a1-GFPhigh PMo were recruited to tumor
cell clusters within 30 min after IV tumor in-
jection, and recruitment continued for at least
7 days (Fig. 1, D and E, and movies S2 to S5).
Nr4a1-GFPhigh cells that were recruited to lung
tumor sites were not positive for Ly6C/G (GR-1)
in vivo, further confirming that these Nr4a1-
GFPhigh cells are not Ly6G+ granulocytes or Ly6C+
classical monocytes (movie S4). The kinetics of
PMo recruitment to the lung differed from that
of Ly6C+monocytes (fig. S2A). At 7 days, therewere
significantly higher numbers of Nr4a1-GFPhigh
PMo (~24/100 mm3) associated with tumor areas
compared with tumor-free areas, confirming ac-
tive recruitment of PMo to the tumor (Fig. 1, D
and E; movie S5; and fig. S1B).
Nr4a1-GFPhigh monocytes patrolling the vas-
culature 4 hours after tumor injection appeared
to move toward and inhibit the attachment of
tumor cells to the lung microvasculature (movie
S3). We examined whether Nr4a1-GFPhigh PMo
could extravasate outside the vasculature. We
found that by 4 hours after tumor injection, 10
to 20% of Nr4a1-GFPhigh PMo had extravasated
at tumor sites (fig. S2, B and C), and this increased
to 40 to 50% PMo extravasation by 7 days. To-
gether, these findings confirm that PMo establish
early immune interactions with tumor cells and
can extravasate and accumulate at tumor sites.
To determine whether PMo have a major role
in regulating tumor invasion, metastasis, and
growth in the lungs in vivo, we used Nr4a1 knock-
out (Nr4a1−/−) mice, which exhibit selective loss
of PMo (10) (fig. S3). Nr4a1−/− mice were IV in-
jected with either syngeneic B16F10 melanoma
cells expressing a luciferase reporter or LLC-RFP
cells (Fig. 2, A and B, and figs. S4 and S5). As early
as 24 hours and up to 21 days after IV injection of
B16F10melanoma, we observed increased tumor
invasion in the lungs ofNr4a1−/−mice compared
with control mice (Fig. 2, A and B, and fig. S4, A
and B). We observed no differences in either
Ly6C+ monocyte or Ly6G+ granulocyte popula-
tions in the lungs of these mice 7 days after tu-
mor injection (fig. S4C). B16F10 tumor invasion
appeared to be specific for the lung, as increased
tumor metastasis was not observed in the liver
(fig S4B). Additionally, increased spontaneous
metastases to the lung were observed in Nr4a1−/−
mice after subcutaneous injection of B16F10mela-
noma, which suggests that Nr4a1 expression is
important for suppressingprimary tumormetastasis
to the lung (Fig. 2C). A similar early and sustained
increase in lungmetastasis inNr4a1−/−mice was
also observed after intravenous LLC tumor trans-
fer (fig. S5). We did not detect differences in lung
vascular permeability between Nr4a1−/− and con-
trol mice (fig. S6).
We next investigated the mouse mammary tu-
mor virus–polyomamiddle T (MMTV-PyMT)mod-
el, in which female mice spontaneously develop
mammary tumors that metastasize to the lung
(15). To focus on Nr4a1 function exclusively in
hematopoietic cells, we performed bone marrow
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Fig. 1. Nr4a1-GFPhigh monocytes patrol the vasculature and interact with
tumor cells in the lung. (A) Quantification of Nr4a1-GFPhigh PMo per
microliter of blood volume in lung for control tissue (Untreated) or 4 or
24 hours after IV LLC-RFP transfer (n = 5mice per group). (B) Quantification
of Nr4a1-GFPhigh monocyte movement in the lung before (Untreated), 4 hours
after, or 24 hours after LLC-RFP tumor injection. (Left) Monocyte tracks
transposed to a common origin from a representative 20-min movie (scale
bar, 100 mm). (Right) Quantification of median speed ofmonocytes (combined
speed data from analysis of three separate mice; *P < 0.001 lower than
untreated; **P < 0.001 lower than 4-hour tumor). (C) Representative gating
of Nr4a1-GFPhighCD11b+ cells from all live CD45+CD11clow cells 24 hours
after IV LLC-RFP transfer. (D) Representative confocal image of Nr4a1-
GFPhigh monocytes (green) interacting with LLC-RFP cells (red) in the lung
7 days after IV LLC-RFP transfer. Immune cells in the vasculature were
labeled with IV-injected antibody to CD45 (blue). (E) Quantification of free
(>100 mm from tumor site) and tumor-associated (<50 mm from tumor
site) Nr4a1-GFPhigh monocytes in the lung at various time points after tumor
injection (combined analysis of five mice per group; P < 0.01 for each tumor-













transplants using either wild-type (WT) orNr4a1−/−
bone marrow transferred into female recipient
MMTV-PyMT mice. MMTV-PyMT mice receiving
Nr4a1−/− bone marrow developed significantly
higher numbers of spontaneous metastases to
the lung but no differences in primarymammary
tumor growth compared to mice receiving WT
bone marrow (Fig. 2, D and E).
We further tested hematopoietic Nr4a1 func-
tion using B16F10melanoma. Onlymice receiving
Nr4a1−/− bone marrow had increased B16F10 tu-
mor metastases, confirming that Nr4a1 expres-
sion in hematopoietic cells regulated tumor cell
metastasis to the lung (fig. S7, A and B). Analysis
of immune cells isolated from lung tumors verified
a selective loss of PMo in Nr4a1−/− bone marrow–
transplanted mice (fig. S7C). In the 1:1 chimera
mice, we observed equal reconstitution of im-
mune cells from each donor (fig. S7D). However,
PMo were derived almost exclusively from WT
bone marrow, suggesting that the restoration of
the Ly6C− monocyte population prevented tu-
mor metastasis.
To confirm that Nr4a1 expressed in myeloid
cells was regulating tumor metastasis to the
lung,we examined two differentmyeloid-specific
Nr4a1 conditional knockout models (CSF1R-
Cre+Nr4a1fl/fl and LysM-Cre+Nr4a1fl/fl). Deletion
of Nr4a1 using CSF1R-Cre+Nr4a1fl/fl and LysM-
Cre+Nr4a1fl/fl mice significantly reduced the num-
ber of PMo in circulation (fig. S8) and increased
tumor lungmetastasis (Fig. 3, A and B, and fig. S9).
Nr4a1 deletion using CSF1R-Cre or LysM-Cre also
targets Nr4a1 in macrophages and Ly6C+ mono-
cytes, so we cannot completely rule out effects of
Nr4a1 in these cells. However, Nr4a1 expression
in macrophages and Ly6C+ monocytes is rela-
tively low, which suggests limitedNr4a1 function
(10, 16, 17). Nodifferences in tumormetastasiswere
observed with T lymphocyte–specific Nr4a1 dele-
tion (fig. S10). Collectively, our studies illustrate
increased lung metastasis burden in the absence
ofNr4a1 inmyeloid cells inmultiple cancermodels.
To confirm a direct role for PMo in regulating
tumormetastasis, WT Ly6C+ or Ly6C−monocytes
were adoptively transferred into recipientNr4a1−/−
mice before tumor injection. A substantial num-
ber of the transferred monocytes could be found
in the lungs (fig. S11, A and B). Reconstitution of
PMo into Nr4a1−/− mice prevented lung tumor
metastasis (Fig. 3, C and D). In contrast, transfer
of Ly6C+ monocytes into Nr4a1−/− mice actually
promoted tumormetastasis, consistentwithknown
protumoral properties of this subset of mono-
cytes (5, 18). The majority (80 to 90%) of trans-
ferred Ly6C+ monocytes in circulation did not
lose Ly6C expression (fig. S11C). Transfer of PMo
24 hours after tumor injection into Nr4a1−/− mice
did not suppress tumor metastasis (fig. S11D), sug-
gesting that PMo must already be present and
active in the vasculature to prevent early tumor
metastasis. These data directly show that non-
classical PMo inhibit tumormetastasis to the lung.
Patrolling monocytes can act as “intravascular
housekeepers” that scavenge microparticles and
remove cellular debris from the microvascula-
ture (7). Extracellular vesicles from tumors are
important mediators of tumor metastasis, pro-
gression, and immune suppression, and target-
ing their removal is an emerging focus for cancer
therapy (19, 20). We used high-resolution con-
focal imaging to determine whether PMo could
engulf and remove tumormaterial from the lung
vasculature. A sizable number of Nr4a1-GFPhigh
PMo containing large amounts of LLC-RFP tumor
material were observed at tumor sites in the lung
24 hours after IV tumor transfer (Fig. 3E). Co-
culture assays of mouse PMo with fluorescently
labeled tumor cells confirmed engulfment of
large amounts of tumormaterial (Fig. 3F). Analy-
sis of monocyte populations isolated from the
lung at 24 hours after IV LLC-RFP injection indi-
cated that PMo preferentially took up ~fivefold
more tumor material than did Ly6C+ classical
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Fig. 2. Increased lung metastasis of tumors in Nr4a1−/− mice. (A) (Left)
In vivo luciferase detection in WTcontrol and Nr4a1−/− mice 24 hours after IV
injection of 5 × 105 B16F10 melanoma cells expressing luciferase. (Right)
Luciferase quantification (*P < 0.03, representative experiment with five mice
per group). (B) In vivo luciferasedetection (left) and quantification (right) inWT
andNr4a1−/−mice 7 days after IV injection with 3 × 105 B16F10-luciferase cells
(*P <0.001, n= 18mice per group combined from three separate experiments).
(C) Number of spontaneous tumor metastases per 5000 mm2 of lung surface
28 days after subcutaneous injection of 1 × 105B16F10-YFPcells (*P<0.01, n=7
mice per group). (D and E) Lung tumor metastasis in MMTV-PyMT mice
reconstituted with WT (WT:PyMT) or Nr4a1−/− (Nr4a1−/−:PyMT) bone marrow.
(D) (Left) Representative MMTV-PyMT mouse lung histology, stained with
hematoxylin and eosin. (Right) Quantification of the number of spontaneous
lung metastases per 5000 mm2 of lung surface (*P < 0.05, n = 12 for WTand 15
forNr4a1−/−). (E) Quantification of primary breast tumor growth inMMTV-PyMT












monocytes (Fig. 3G). PMo also preferentially took
up substantially more B16F10–yellow fluorescent
protein (YFP) tumor material, with an average
tumor material size of 1.39 mm2 and an average
total amount of tumor material per monocyte of
1.92 mm2 (fig. S12, A and B). The homologous
human CD14dimCD16+ population of PMo, which
similarly has high Nr4a1 expression (8, 21),
also engulfed a large quantity of tumor material
in vitro, suggesting analogous tumor engulfment
function (fig. S12C). Moreover, PMo actively en-
gulfed tumor material within classic endocytic
compartments (22) (Fig. 4A). Collectively, these
results demonstrate that Nr4a1-dependent PMo
rapidly and preferentially endocytose tumor
material.
We then asked how PMo recognized tumor
cells to preventmetastasis in the lung. The chemo-
kine receptor CX3CR1 is highly expressed on PMo
and is important for their arrest at inflammatory
sites (fig. S13A) (23–25). CX3CR1-deficient(Cx3cr1−/−)
mice, which also have a significant reduction in
PMo, exhibit a similar phenotype toNr4a1−/−mice
(i.e., increased tumor burden and metastasis to
the lung) (26, 27). Although PMo numbers were
reduced in the lung vasculature of Cx3cr1−/−mice
[~30 to 50% reduction (fig. S13B), confirming pre-
vious reports] (27), a major proportion of the
remaining CX3CR1-deficient PMo was observed
patrolling the vasculature, as previously observed
(7). Unlike Cx3cr1−/+or WT PMo, Cx3cr1−/− PMo
did not arrest near LLC tumor cells and instead
remained patrolling within the lung vasculature
(Fig. 4, B and C, and movie S6). Cx3cr1−/− PMo
were not recruited to the lung 24 hours after LLC
tumor challenge, whereas Ly6C+ recruitment was
unaffected by the loss of CX3CR1 expression (fig.
S13B). Cx3cr1−/− PMo present in the lung showed
defective engulfment of tumor material, indicat-
ing that CX3CR1 expression on PMo is critical for
mediating the sensing and uptake of tumor ma-
terial (Fig. 4D).
CX3CL1, a ligand for CX3CR1, has been re-
ported to be present in high levels in human and
mouse lungs (28). Using a CX3CL1-mCherry re-
porter mouse (29), we found that CX3CL1 was
specifically expressed on CD31+ endothelial cells
(ECs) at low levels in the lung microvasculature
(Fig. 4, E and F, and fig. S13C). CX3CL1 expres-
sion was most prevalent in lung ECs compared
with ECs in other tissues (fig. S13D), which may
partially explain the enrichment and preferential
function of PMo in the lung. CX3CL1 expression
on lung ECs increased in response to tumor chal-
lenge (Fig. 4E) and at sites of tumor metastasis
(Fig. 4F), consistent with reports of increased
CX3CL1 during lung inflammation (30).
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Fig. 3. Nr4a1-expressing PMo reduce tumor metastasis and engulf tu-
mor material in the lung. (A) In vivo imaging (left) and quantification (right)
of lung tumors in CSF1R-Cre−Nr4a1fl/fl (CSF1R-Cre−) or CSF1R-Cre+Nr4a1fl/fl
(CSF1R-Cre+) mice 7 days after IV injection of 3 × 105 B16F10-luciferase tu-
mor cells (n = 6 mice per group, *P < 0.01; experiment replicated twice).
(B) Quantification of the number of tumor metastases per lung of CSF1R-
Cre−Nr4a1fl/fl (CSF1R-Cre−) and CSF1R-Cre+Nr4a1fl/fl (CSF1R-Cre+) mice
7 days after IV injection of 3 × 105 B16F10-YFP tumor cells (n = 8 mice per
group, *P<0.01). (C andD)Nr4a1−/−micewere injected intravenously with 5 ×
105WT Ly6C−PMo, Ly6C+ inflammatorymonocytes, or PBS at day 0.On day 1,
3 × 105 B16F10-luciferase tumor cells were injected intravenously, and tumor
metastasis and growth were measured by in vivo imaging on day 8. Shown are
representative in vivo images (C) and quantification (D) of B16F10-luciferase
metastasis 8 days after monocyte transfer and 7 days after tumor transfer
in WTorNr4a1−/−mice (combined data from five separate experiments with
n = 2 mice per group; *P < 0.01 statistically different from WT; **P < 0.05
statistically different from Nr4a1−/−). (E) Imaging of tumor material uptake
in lung by Nr4a1-GFPhigh monocytes 24 hours after IV injection of LLC-RFP
tumor cells. Representative higher-magnification images are shown at right.
Note that Nr4a1-GFP expression is primarily nuclear, so monocyte cell mem-
branes are not visible in these images. (F) Uptake of LLC-RFP tumor material
by CX3CR1-GFPhighLy6C− PMo after 24 hours of coculture. (G) Representa-
tive flow plot (left) and quantification (right) of tumor material uptake by all
monocytes in the lung 24 hours after IV tumor injection of 3 × 105 LLC-RFP
cells (n = 4 mice per group; *P < 0.01; experiment replicated three times).












Toll-like receptor 7 (TLR7) has been linked to
recruitment of PMo in response to kidney dam-
age in mice (7). However, we found that TLR7
did not play a major role in either recruitment of
PMo to the lung after tumor injection (fig. S13B)
or uptake of tumor material by PMo (Fig. 4D).
We conclude that both CX3CR1 expression on
monocytes and CX3CL1 expression by ECs are
critical for recruitment of PMo to sites of tumor
extravasation to mediate the removal of tumor
material from the lung. CX3CL1 expression by tu-
mor cells (31)may also drivemonocyte recruitment.
In agreement with our findings, many studies
have reported that CX3CL1 expression by either
tumor cells or tumor-associated cells is anti-
tumoral and correlated with good prognosis
(32–34). However, the function of the CX3CL1/
CX3CR1 axis, particularly during later stages of
tumor growth, is complex (35, 36).
Finally, we examinedwhether PMo can directly
kill tumor cells. After multiple attempts using var-
ious experimental conditions, direct killing of tu-
mor cells by PMo was not observed (fig. S14).
However, PMo may be important for antibody-
dependent cell-mediated cytotoxicity of either tu-
mor cells or suppressive immune cells within the
tumor environment (37, 38). In response to IV-
injected B16F10 tumor, PMo isolated from lungs
produced significantly higher levels of natural
killer (NK) cell activation and recruitment-related
chemokines CCL3, CCL4, andCCL5, as compared
with classical Ly6C+monocytes (Fig. 4G) (39, 40).
In accordwith this finding,myeloid-specific Nr4a1
knockout mice (CSF1R-Cre+Nr4a1fl/fl) showed
reduced NK cell recruitment to the lung in re-
sponse to tumor (Fig. 4H), suggesting that PMo
controlled the recruitment of NK cells to tumor
sites. A similar reduction in NK cell recruitment
and CD44 activation (fig. S15, A and B) was also
observed in the lungs of PyMTmice that received
Nr4a1-deficient bone marrow. However, Nr4a1
does not regulate NK cell development (fig. S15C).
Uptake of tumor material by PMo does not re-
quire the presence of NK cells (fig. S16, A and B).
NK cell depletion reduced the differences in
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Fig. 4. Patrolling monocytes detect tumor material in a CX3CR1-dependent
manner and recruit NK cells to the lung tumor environment. (A) Ratio of
fluorescent intensity of tumor material engulfed by PMo (black) to fluorescent
intensity of whole tumor (black and gray) 3 hours after IV LLC tumor injection.
LLC tumors were labeled with either CellTrace Violet control dye (Control) or a
pH-sensitive pHrodo Red dye (pHrodo) and then intravenously injected in a 1:1
ratio into a WT mouse (n = 3 mice per group, experiment replicated three
times). Representative tracking (B) and median speed (C) of Cx3cr1−/− or
Cx3cr1−/+ monocyte movement 24 hours after IV tumor injection in the lung.
Monocyte tracks transposed to a common origin from representative 20-min
movies (scale bar, 100 mm; representative tracks are shown from one mouse,
median speed was calculated from tumor areas analyzed in three separate
mice per group, *P < 0.001). (D) (Left) Percentage of Ly6C− PMo containing
LLC-RFP tumor material in the lung 3 hours after IV injection of tumor into
representative WT, Cx3cr1−/−, or Tlr7−/− mice. (Right) Quantification of tumor
material uptake (n = 3 per group, *P < 0.001 versus WT). (E) Percentage of
CD31+ CX3CL1+ lung ECs isolated from untreated (UN) mice or from CX3CL1-
mCherry mice, 24 hours or 7 days after IV injection of B16F10-YFP tumor cells.
(F) Representative imaging of CX3CL1-mCherry (red) expression in lung
24 hours after IV injection of B16F10-YFP tumor cells (green) in CX3CL1-
mCherry mice. CD45+ immune cells are labeled in blue. (G) Relative chemo-
kine mRNA expression in Ly6C+ or Ly6C− monocytes isolated from lungs by
fluorescence-activated cell sorting 24 hours after IV B16F10 tumor injection
(monocyte populations isolated from three separate mice; *P < 0.01; experi-
ment repeated three times). (H) Percentage of NK cells in the lungs of CSF1R-
Cre−Nr4a1fl/fl (CSF1R-Cre−) or CSF1R-Cre+Nr4a1fl/fl (CSF1R-Cre+) mice 7 days
after IV injection of 3 × 105 B16F10-luciferase tumor cells (n=6mice per group,












metastasis between WT and CSF1R-Cre+Nr4a1fl/fl
mice (fig. S16C). Thus, PMo inhibit metastasis, at
least in part, through the regulation of NK cell
recruitment and activity.
In summary, we demonstrate that PMo partic-
ipate in cancer surveillance by preventing tumor
metastasis to lung. PMo are actively recruited
to lung metastasis sites in a CX3CR1-dependent
manner, where they function to scavenge tumor
material, as well as to recruit and activate NK
cells, leading to the prevention of tumor cell me-
tastasis (fig. S17). Selective targeting by increas-
ing PMo activity and/or their regulation by Nr4a1
may represent a novel therapy for the prevention
of cancer metastasis to the lung.
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the lung, where they engulfed tumor material, which may explain how these cells prevent tumors from colonizing the 
showed increased metastasis to the lung but not to other tissues. Patrolling monocytes resided in the microvasculature of
monocytes in blocking tumor metastasis to the lungs in mice. Tumors in mice engineered to lack patrolling monocytes 
 now report a role for patrollinget al.to understand the cellular events that promote or prevent metastasis. Hanna 
Metastatic cancer is especially hard to treat. In order to find potential new therapeutic targets, scientists are trying
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